Healthcare
Globus Medical, Inc.(GMED)
Live Price
Offline$79.19
-0.05% today
1Y Change
+32.88%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $12.17B
- Revenue Growth
- +16.7%
- EPS Growth
- +423.7%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Globus Medical, Inc. (GMED) is a Healthcare stock with a market cap of $12.17B and listed on NYSE. The stock last traded around $79.19 and up 32.9% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +16.7%, EPS growth of +423.7%, a dividend yield of 0.0%. What stands out right now is revenue +16.7%, EPS +423.7%, free cash flow +45.3% with operating margin 16.3% and ROIC 8.8%. Valuation sits in the middle of the pack at P/E 22.6 and price/sales 4.1. Stock Foundry combines GMED price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.7% vs +7.6% peer median
Operating Margin
Below sector median
+16.3% vs +19.4% peer median
P/E
Below sector median
22.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.7% and EPS at +423.7%, with operating margin around 16.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +15.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.7% | +9.6% | +4.1% |
2026 Feb 24, 2026 | +20.8% | +4.7% | -0.2% | -6.1% |
2025 Nov 6, 2025 | +51.1% | +35.9% | +36.1% | +47.6% |
Benchmark Edge
GMED vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GMED
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GMED Max Drawdown
-21.95%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GMED and SPY.
Company Overview
Globus Medical, Inc.
New York Stock Exchange
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
- Leadership
- Keith W. Pfeil
- IPO Date
- Aug 3, 2012
- Employees
- 5.3k
- Street Address
- 2560 General Armistead Avenue
- Mailing
- Audubon, PA, 19403
- Region
- Audubon, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 930 1800
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.6
- EV/EBITDA
- 14.4
- Price/Sales
- 4.1
- Price/Book
- 2.7
Growth
- Revenue
- +16.7%
- EPS
- +423.7%
- Free Cash Flow
- +45.3%
Profitability
- Gross Margin
- 67.4%
- Operating Margin
- 16.3%
- Net Margin
- 18.3%
- ROE
- 12.4%
- ROIC
- 8.8%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 4.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.